Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04932096 · ClinicalTrials.gov registry record · Phase 2

Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin

A Phase 2 study, sponsored by Oregon Health and Science University.

Completed
Registry status
Phase 2
Development phase
21
Enrollment target

NCT04932096: Completed Phase 2 study, sponsored by Oregon Health and Science University.

NCT04932096 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04932096, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
Phase 2
Development phase
21 participants
Enrollment target

Study Summary

Sleep wake disturbances compound recovery in over half of pediatric traumatic brain injury survivors, leading to impaired quality of life, and few effective interventions exist to treat this important morbidity. Therefore, this study will conduct a randomized controlled trial evaluating a melatonin intervention started during hospitalization and continued after discharge compared to placebo. The trial will investigate if this intervention is feasible, acceptable, and effective at reducing sleep wake disturbances as measured on the Sleep Disturbances Scale for Children 1-month after hospital discharge. Participants will be randomly assigned to receive the intervention (melatonin) or to the control group (placebo) with a goal of equal numbers of participants in each group and all will receive sleep education. Participants will be followed closely after consent and outcomes will be assessed at hospital discharge, and 1-month. Outcomes will focus on feasibility (ability to recruit patients into the trial) and acceptability (patient safety and satisfaction), but will also assess the effectiveness of the intervention to reduce sleep disturbances after discharge. The investigators will assess sleep using questionnaires and actigraphy (watch-like activity monitors). Exploratory outcomes will include global health outcomes.

Primary Outcome

Sleep Disturbances Scale for Children (SDSC): 26-item parent proxy sleep questionnaire with higher scores reflecting greater disturbance and risk for clinically important sleep disorders. Each question is scored 1 through 5 for a range of possible total scores of 26 - 130. Raw scores are converted to measure defined T-scores (mean=50, SD=10) for the total score and 6 subscale scores with higher scores indicating worse dysfunction, and T-scores greater than 60 generally indicating clinically sign

Interventions

  • OTHER placebo
  • DRUG melatonin

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2023-01-02
Est. Completion 2025-03-01
Phase Phase 2

What the finished NCT04932096 record still lists

NCT04932096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT04932096 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04932096 about?

NCT04932096 is a clinical study titled "Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin". Sleep wake disturbances compound recovery in over half of pediatric traumatic brain injury survivors, leading to impaired quality of life, and few effective interventions exist to treat this important morbidity. Therefore, this study will conduct a randomized controlled trial evaluating a melatonin ...

What is the current status of trial NCT04932096?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2023-01-02. Estimated completion is 2025-03-01.

What interventions are being tested in trial NCT04932096?

The interventions under investigation include: placebo (OTHER), melatonin (DRUG).

Who is sponsoring clinical trial NCT04932096?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04932096's enrollment target sits among peer trials

21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04932096, the US trial registry maintained by the National Library of Medicine. NCT04932096 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.